4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

EMERYVILLE, Calif., June 08, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics¬†(Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today presented supplemental aflibercept injection-free subgroup analyses of the previously reported 24-week landmark results…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks